These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32564819)

  • 41. Effects of sodium hyaluronate on wavefront aberrations in dry eye patients.
    Lekhanont K; Chuckpaiwong V; Vongthongsri A; Sangiampornpanit T
    Optom Vis Sci; 2014 Jan; 91(1):39-46. PubMed ID: 24366433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye.
    Matsuo T
    Jpn J Ophthalmol; 2004; 48(4):321-7. PubMed ID: 15295655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lifitegrast (Xiidra) for dry eye disease.
    Med Lett Drugs Ther; 2016 Aug; 58(1502):110-1. PubMed ID: 27552207
    [No Abstract]   [Full Text] [Related]  

  • 44. A Randomized Controlled Double-Masked Study of Transdermal Androgen in Dry Eye Patients Associated With Androgen Deficiency.
    Supalaset S; Tananuvat N; Pongsatha S; Chaidaroon W; Ausayakhun S
    Am J Ophthalmol; 2019 Jan; 197():136-144. PubMed ID: 30268865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A molecular marker for dry eye].
    Pintor J
    Arch Soc Esp Oftalmol; 2007 Mar; 82(3):129-30. PubMed ID: 17357887
    [No Abstract]   [Full Text] [Related]  

  • 46. Tear break-up time for tear film evaluation: Are moistening solutions interchangeable?
    Serés C; Quevedo L; Cardona G; Blanch El; Augé M
    Cont Lens Anterior Eye; 2015 Aug; 38(4):272-6. PubMed ID: 25814428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient perceptions of autologous serum eye drops for severe dry eye disease.
    Yu AT; Lee GA; Vincent S; Shah P
    Clin Exp Ophthalmol; 2020 Nov; 48(8):1109-1111. PubMed ID: 32710460
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye.
    Christensen MT; Cohen S; Rinehart J; Akers F; Pemberton B; Bloomenstein M; Lesher M; Kaplan D; Meadows D; Meuse P; Hearn C; Stein JM
    Curr Eye Res; 2004 Jan; 28(1):55-62. PubMed ID: 14704914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
    Mandal A; Gote V; Pal D; Ogundele A; Mitra AK
    Pharm Res; 2019 Jan; 36(2):36. PubMed ID: 30617777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness.
    Veldman P; Colby K
    Int Ophthalmol Clin; 2011; 51(4):43-52. PubMed ID: 21897139
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
    Mun Y; Kwon JW; Oh JY
    BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment and treatment of the dry eye in leprosy.
    Passerotti S; Salotti RA; Vieth H
    Indian J Lepr; 1998; 70(1):103-8. PubMed ID: 9598411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter, double-blind, parallel group, placebo-controlled clinical study to examine the safety and efficacy of T-Clair SPHP700-3 in the management of mild to moderate dry eye in adults.
    Villani E; Laganovska G; Viola F; Pirondini C; Baumane K; Radecka L; Ratiglia R
    Cornea; 2011 Mar; 30(3):265-8. PubMed ID: 21099417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS; O'Brien T; Kim T; Torkildsen G
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lubricant with gelling agent in treating dry eye in adult Chinese patients.
    Waduthantri S; Yong SS; Tan CH; Htoon HM; Tong L
    Optom Vis Sci; 2012 Nov; 89(11):1647-53. PubMed ID: 23069726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye.
    Johnson ME; Murphy PJ; Boulton M
    Graefes Arch Clin Exp Ophthalmol; 2006 Jan; 244(1):109-12. PubMed ID: 15983814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.